Drugs / LY3844583
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05486208 | Aug 2022 → Jan 2024 | atopic eczema | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3844583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05486208 ↗ |
| Route | Intravenous | “Administered SC and/or IV.” NCT05486208 ↗ |
| Route | Subcutaneous | “Administered SC and/or IV.” NCT05486208 ↗ |